目的 探讨¹³¹I治疗儿童及青年格雷夫斯病（GD）的疗效及其影响因素。方法 回顾性分析2013年—2022年在简阳市人民医院核医学科院接受¹³¹I治疗且年龄≤22岁的儿童及青年GD患者的临床资料。采用个体计算剂量法,每克甲状腺组织的计划用量为80~140 μCi,依据甲状腺吸碘率及甲状腺质量,确定¹³¹I的用量。依据¹³¹I治疗后3~6个月的甲状腺功能指标,进行疗效评价,甲状腺功能恢复正常或发生甲减视为治愈。统计分析治愈组与非治愈组间的临床疾病特征参数,评估可能影响疗效的因素。结果 纳入患者71例：男23例、女48例,年龄11~22岁。患儿甲状腺质量4.8~60.0 g,均值22.1 g。¹³¹I的用量在6~24 mCi,均值11.3 mCi。49例（69%）患者获得治愈,22例（31%）未获治愈。单因素分析显示年龄、性别、促甲状腺激素受体抗体的滴度、甲状腺吸碘率、甲状腺质量及¹³¹I用量等,治愈组与非治愈组间比较差异均无统计学意义（均P>0.05）。结论 以每克甲状腺组织80~140 μCi的计划用量,确定¹³¹I用量治疗儿童青年GD的疗效可达69%。

Objective To investigate the effect of ¹³¹I on Graves' disease（GD）in children and young adults and its influencing factors．Methods The clinical data of GD patients aged ≤22 who received ¹³¹I treatment in Nuclear Medicine Department of Jianyang People's Hospital from 2013 to 2022 were retrospectively analyzed．The planned dosage of ¹³¹I was 80~140 μCi per gram of thyroid tissue,and the dosage of ¹³¹I was determined according to the iodine uptake rate and thyroid mass．According to the thyroid function indicators of 3 to 6 months after ¹³¹I treatment,the curative effect was evaluated,and the thyroid function returned to normal or hypothyroidism occurred were considered as cured．The clinical characteristic parameters of the cured group and the non-cured group were analyzed to evaluate the factors that might affect the curative effect．Results Seventy-one patients were included：23 males and 48 females,aged 11-22．The thyroid mass of the children ranged from 4.8 to 60.0 g,with an average of 22.1 g．The dosage of ¹³¹I ranges from 6 to 24 mCi,with an average of 11.3 mCi．Forty-nine patients（69%）were cured and 22（31%）were not cured．Univariate analysis showed that there were no significant differences in age,sex,titer of thyrotropin receptor antibody,thyroid iodine uptake rate,thyroid mass and ¹³¹I dosage between the cured group and the non-cured group（all P>0.05）．Conclusions With the planned dosage of 80~140 μCi per gram of thyroid tissue,the efficacy of ¹³¹I in the treatment of GD in children and young adults can reach 69%．

目的 探讨¹³¹I联合甘氨双唑钠治疗分化型甲状腺癌(differentiated thyroid carcinoma,DTC)骨转移的临床疗效。方法 以我院96例DTC骨转移患者为研究对象,随机分为对照组和观察组各48例,对照组仅予¹³¹I治疗,观察组予¹³¹I联合甘氨双唑钠治疗,比较两组的临床疗效、转移灶清除效果及不良反应。结果 根据骨痛评价标准,观察组的有效率(71.00%)高于对照组(48.00%)(P＜0.05)。根据血清甲状腺球蛋白(thyroglobulin,Tg)评价标准,观察组的有效率(77.00%)高于对照组(58.00%)(P＜0.05)。根据病灶影像学评价标准,观察组的有效率(48.00%)高于对照组(27.00%)(P＜0.05)。两组不良反应发生率差异无统计学意义(P＞0.05)。结论 ¹³¹I联合甘氨双唑钠可提高DTC骨转移患者临床疗效,具有临床推广意义。

Objective To explore the clinical effect of ¹³¹I combined with sodium glycididazole in the treatment of differentiated thyroid cancer (DTC) with bone metastasis. Methods Ninty-six patients with DTC bone metastasis were randomly divided into the control group and the observation group, forty-eight patients in each group. The control group was treated with ¹³¹I only, while the observation group was treated with ¹³¹I combined with glycididazole sodium. The clinical effect, metastasis clearance effect and adverse reactions of the two groups were compared. Results The effective rate of the observation group (71.00%) was higher than that of the control group (48.00%) (P<0.05) according to the evaluation criteria of bone pain. The effective rate of the observation group (77.00%) was higher than that of the control group (58.00%) (P<0.05) according to the evaluation criteria of serum thyroglobulin (Tg). The effective rate of the observation group (48.00%) was higher than that of the control group (27.00%) (P<0.05) according to the imaging evaluation criteria. There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The combination of ¹³¹I and sodium glycidazole can improve the clinical effect of patients with DTC bone metastasis, which has clinical significance for promotion.

目的 研究放射性 ¹³¹I 在甲亢伴甲状腺结节中的应用价值。方法 纳入我院90例甲亢患者,根据其是否伴甲状腺结节分为无结节组(51例)、结节组(39例),均接受放射性 ¹³¹I 治疗。比较两组治疗总有效率,分析两组治疗前后血清甲状腺过氧化物酶抗体(TPOAb)、甲状腺球蛋白抗体(TGAb)、促甲状腺激素(TSH)、游离三碘甲腺原氨酸(FT3)及游离甲状腺素(FT4)水平。结果 无结节组治疗总有效率74.51%,结节组为58.97%,差异无统计学意义(P＞0.05);两组治疗后TSH均高于治疗前(P＜0.05),FT3、FT4均低于治疗前(P＜0.05),TPOAb、TGAb较治疗前比较差异均无统计学意义(P＞0.05);无结节组治疗后FT3、FT4低于结节组(P<0.05),TPOAb、TGAb、TSH较结节组比较差异均无统计学意义(P＞0.05)。结论 放射性 ¹³¹I 治疗甲亢伴甲状腺结节效果好,且操作简单,副作用少,值得临床推广使用。

Objective To study the value of radioactivity ¹³¹I in hyperthyroidism with thyroid nodules. Methods Ninety patients with hyperthyroidism in our hospital were divided into non-nodule group (51 cases) and nodule group (39 cases) according to whether they had thyroid nodules or not. All patients received ¹³¹I radiation therapy. The total effective rate was compared between the two groups. The serum levels of thyroid peroxidase antibody (TPOAb), thyroglobulin antibody (TGAb), thyroid stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) were analyzed before and after treatment. Results The total effective rate was 74.51% in non-nodule group and 58.97% in nodule group, with no significant difference (P>0.05);after treatment, TSH was higher in both groups than that before treatment (P<0.05), FT3 and FT4 were lower than that before treatment (P<0.05), TPOAb and TGAb had no significant difference compared with that before treatment (P>0.05);FT3 and FT4 in nodule-free group were lower than those in nodule group (P<0.05). TPOAb, TGAb and TSH had no significant difference compared with nodule group (P>0.05). Conclusion Radioactive ¹³¹I treatment of hyperthyroidism with thyroid nodules has good effect, simple operation and few side effects, which is worthy of clinical application.